Literature Title | First Author | Type | Publication Year | Publication Journal | Brief Summary | Clinical Practice Pearl | Reference # |
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Garvey | Original Research | 2022 | Nature Medicine | Once-weekly subcutaneous semaglutide enhances weight loss and patient-reported quality of life outcomes in obese patients. Weight loss in the semaglutide group was 11% more than placebo. However, the trial primarily focuses on patient-reported outcomes, necessitating further research to understand broader clinical implications. The mechanism for quality-of-life improvements and the impact of SGLT2 inhibitors require exploration. Larger studies are needed to assess GLP-1 receptor agonists’ utility. | Semaglutide was superior to placebo in weight loss in obese patients | 11 |
Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. | Ghusn | Retrospective Original Research | 2022 | JAMA Network | Adult with a BMI of 27+, receiving 3 - 6 months of semaglutide injections, achieved significant weight loss: 6.7 kg (5.9%) at 3 months and 12.3 kg (10.9%) at 6 months. Patients with type 2 diabetes had lower weight loss rates. Strengths include real-world data and a sizable sample. Limitations include the absence of a control group and potential recall bias. | Semaglutide is safe and effective in reducing weight in real-world settings | 12 |
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial | Wadden | Original Research | 2021 | JAMA Network | Obese non-diabetic adults received once-weekly subcutaneous semaglutide + intensive behavioral therapy and an initial low-calorie diet achieved significantly greater weight loss over 68 weeks compared to placebo, with a mean body weight change of −16.0% vs. −5.7% in placebo group. Gastrointestinal adverse events were more common with semaglutide, emphasizing the need for long-term sustainability assessment. | Semaglutide + intensive behavioral therapy + initial low-calorie diet leads to weight loss in non-diabetic individuals with overweight or obesity | 13 |
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial | Ahren | Original Investigation Original Research | 2017 | The Lancet | Once-weekly subcutaneous semaglutide, outperformed sitagliptin in improving glycemic control and reducing body weight among patients with type 2 diabetes inadequately controlled on metformin, thiazolidinediones, or both. Semaglutide demonstrated superior efficacy without significant safety concerns, making it a promising add-on treatment for this patient population. | Semaglutide showed superiority in efficacy over sitagliptin | 14 |